Page 1

Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical , safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B - cell depletion and meaningful clinical activity , with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration ( FDA ) granted Regenerative Medicine Advanced Therapy ( RMAT ) designation to AlloNK plus rituximab for refractory rheumatoid arthritis ( RA ) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash , cash equivalents and investments of $ 349.4 million as of June 30 , 2026 , expected to fund operations into 2029 SAN DIEGO , August 6 , 2026 -- Artiva Biotherapeutics , Inc. ( Nasdaq : ARTV ) ( Artiva ) , a clinical - stage biotechnology company whose mission is to develop effective , safe and accessible cell therapies for patients with debilitating autoimmune diseases , today announced financial results for the second quarter ended June 30 , 2026 , and highlighted recent progress . " The second quarter was transformative for Artiva . The clinical and translational data presented at EULAR reinforced AlloNK's potential to drive deep B - cell depletion and meaningful clinical responses , with a tolerability profile supportive of outpatient administration . RMAT designation for refractory rheumatoid arthritis , together with FDA alignment on our Phase 3 design , further supports our advancement of AlloNK into registrational development , " said Fred Aslan , M.D. , chief executive officer of Artiva Biotherapeutics . " Having raised approximately $ 300 million in an underwritten offering , we are well capitalized to initiate and execute our planned Phase 3 trial in refractory RA and continue advancing AlloNK across B - cell - driven autoimmune diseases . " Recent Business Highlights Presented clinical , safety and translational data for AlloNK at EULAR 2026 • Refractory RA - response : In the company - sponsored Phase 2a basket trial , five of seven patients ( 71 % ) with six months of follow - up achieved an ACR50 response as of the April 3 , 2026 data cutoff date . These data support the hypothesis being tested in the randomized Phase 3 trial : that AlloNK plus rituximab can achieve an ACR50 response rate greater than 50 % in patients with refractory RA who have had an inadequate response to two or more distinct classes of biologic or targeted synthetic disease - modifying anti - rheumatic drugs ( b / tsDMARDs ) , versus an expected response rate of approximately 20 % with rituximab alone based on published literature and real - world evidence . Refractory RA - durability : As of the April 3 , 2026 data cutoff , no patient had lost response , required high - dose steroids or started a new b / tsDMARD following treatment with AlloNK plus rituximab . The AlloNK regimen can be re - dosed if needed , with the potential to drive long term clinical benefit and freedom from b / tsDMARD therapy . Sjögren disease ( SjD ) and systemic sclerosis ( SSC ) : Patients with SjD ( n = 11 ) demonstrated improvements across clinical , patient - reported and functional measures , including normalization of mean stimulated salivary flow among patients with six months of follow - up ( n = 7 ) as of the data cutoff date . Patients with SSc ( n = 5 ) demonstrated improvements in mean modified Rodnan skin score ( mRSS ) ; among patients with six months of follow - up ( n = 4 ) , mRSS decreased by 9.5 points on average , and all achieved rCRISS25 as of the data cutoff date . Safety and outpatient feasibility : Among 55 safety - evaluable autoimmune patients treated with AlloNK plus rituximab , no cytokine release syndrome ( CRS ) , immune effector cell - associated neurotoxicity syndrome ( ICANS ) , AlloNK - related serious adverse events or treatment discontinuations due to adverse events were observed as of the April 3 , 2026 data cutoff date . The rate of Grade 3 or higher infections was 2 % , and no patients were hospitalized for infection during the initial 28 - day post- treatment period . Two of 55 patients were hospitalized for treatment - emergent adverse events during the initial 28 - day period , neither of which was deemed related to AlloNK .